This liquid biopsy, analyzing circulating tumor DNA (ctDNA) in a blood sample, provides a comprehensive genomic profile of advanced cancers. This profile can identify specific genetic alterations driving tumor growth, enabling oncologists to personalize treatment strategies and monitor treatment response dynamically. For instance, the analysis can reveal mutations that make a tumor susceptible to targeted therapies, potentially guiding clinicians toward the most effective treatment options.
Facilitating personalized medicine in oncology, this approach offers a less invasive alternative to traditional tissue biopsies, especially beneficial for patients with difficult-to-access tumors or those unable to undergo invasive procedures. Its ability to track changes in the tumor’s genetic makeup over time allows for real-time monitoring of treatment effectiveness and the early detection of potential resistance mechanisms. The development and refinement of this technology represent a significant advancement in cancer diagnostics and treatment monitoring, offering new possibilities for improved patient outcomes.
